Skip to Content

Daptomycin Dosage

Applies to the following strength(s): 500 mg

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Skin and Structure Infection

4 mg/kg IV every 24 hours for 7 to 14 days

Use: For the treatment of complicated skin and skin structure infections due to susceptible isolates of Staphylococcus aureus (including methicillin-resistant isolates), Streptococcus pyogenes, S agalactiae, S dysgalactiae subspecies equisimilis, and Enterococcus faecalis (vancomycin-susceptible isolates only)

Usual Adult Dose for Bacteremia

6 mg/kg IV every 24 hours for 2 to 6 weeks

Comments:
-This drug should not be used for the treatment of left-sided endocarditis due to S aureus; in the clinical trial, outcomes were poor.
-This drug has not been studied in patients with prosthetic valve endocarditis.

Uses: For the treatment of S aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, due to methicillin-susceptible and methicillin-resistant isolates

Usual Adult Dose for Endocarditis

6 mg/kg IV every 24 hours for 2 to 6 weeks

Comments:
-This drug should not be used for the treatment of left-sided endocarditis due to S aureus; in the clinical trial, outcomes were poor.
-This drug has not been studied in patients with prosthetic valve endocarditis.

Uses: For the treatment of S aureus bloodstream infections (bacteremia), including those with right-sided infective endocarditis, due to methicillin-susceptible and methicillin-resistant isolates

Renal Dose Adjustments

CrCl less than 30 mL/min:
-Complicated skin and skin structure infections: 4 mg/kg IV every 48 hours
-S aureus bloodstream infections: 6 mg/kg IV every 48 hours

Liver Dose Adjustments

Mild to moderate liver dysfunction: No adjustment recommended.
Severe liver dysfunction (Child-Pugh C): Data not available

Precautions

Safety and efficacy have not been established in patients younger than 18 years; use in patients younger than 12 months should be avoided.

Consult WARNINGS section for additional precautions.

Dialysis

Hemodialysis and CAPD:
-Complicated skin and skin structure infections: 4 mg/kg IV every 48 hours
-S aureus bloodstream infections: 6 mg/kg IV every 48 hours

Comments: This drug should be administered after hemodialysis on hemodialysis days.

Other Comments

Administration advice:
-Administer IV in 0.9% sodium chloride injection either by injection over 2 minutes or by infusion over 30 minutes.
-If same IV line used for sequential infusion of other drugs, flush the line before and after infusion of this drug with a compatible IV solution.

Storage requirements:
-Lyophilized powder: Store original packages under refrigeration, at 2C to 8C (36F to 46F); avoid excessive heat.
-Reconstituted solution: Stable in the vial for 12 hours at room temperature and up to 48 hours when refrigerated at 2C to 8C (36F to 46F)
-Diluted solution: Stable in the infusion bag for 12 hours at room temperature and 48 hours when refrigerated
-Combined storage time (reconstituted solution in vial and diluted solution in infusion bag) should not exceed 12 hours at room temperature or 48 hours when refrigerated.

Reconstitution/preparation techniques:
-The manufacturer product information should be consulted.

IV compatibility:
-Compatible IV solutions: 0.9% sodium chloride injection, lactated Ringer's injection
-Incompatible: Dextrose-containing diluents, ReadyMED(R) elastomeric infusion pumps
-Limited data regarding compatibility with other IV products; additives and other drugs should not be added to this drug or infused concurrently through the same IV line.

General:
-Appropriate specimens for microbiological examination should be obtained before therapy to isolate and identify infecting organisms and to establish susceptibility to this drug.
-Culture and susceptibility information should be considered when selecting treatment or, if no data are available, local epidemiology and susceptibility patterns may be considered when selecting empiric therapy; empiric therapy may be started before test results are known.
-Combination therapy may be clinically indicated if documented or presumed pathogens include gram-negative or anaerobic organisms.
-This drug is not indicated for the treatment of pneumonia.
-Limited safety data for use of beyond 28 days

Monitoring:
-Infections/Infestations: Blood cultures (repeat if persisting or relapsing S aureus bacteremia/endocarditis or poor clinical response); MIC susceptibility (if blood culture positive for S aureus)
-Musculoskeletal: For muscle pain or weakness, especially of distal extremities; creatine phosphokinase (CPK) levels (weekly; more often if CPK elevations during therapy or recent prior/concurrent HMG-CoA reductase inhibitor therapy; more than once a week if renal dysfunction)
-Nervous System: For signs/symptoms of peripheral neuropathy
-Renal: Renal function (more than once a week if renal dysfunction)

Patient advice:
-Avoid missing doses and complete the entire course of therapy.

Hide